$14.64
In the last 3 years, Novo Nordisk A/s has given 176.0% return, outperforming this stock by 37.1%
0.07%
Downside
Day's Volatility :7.05%
Upside
6.99%
78.42%
Downside
52 Weeks Volatility :82.64%
Upside
19.56%
Period | Cymabay Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 73.87% | 0.0% | 0.0% |
6 Months | 63.39% | 3.0% | -0.5% |
1 Year | 312.03% | 7.2% | 0.4% |
3 Years | 138.91% | 27.5% | 19.1% |
Market Capitalization | 1.6B |
Book Value | $1.11 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -0.88 |
PEG Ratio | 0.0 |
Wall Street Target Price | 22.17 |
Profit Margin | -260.27% |
Operating Margin TTM | -231.54% |
Return On Assets TTM | -22.2% |
Return On Equity TTM | -84.59% |
Revenue TTM | 31.0M |
Revenue Per Share TTM | 0.33 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | -41.6M |
EBITDA | -71.0M |
Diluted Eps TTM | -0.88 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.93 |
EPS Estimate Next Year | -1.35 |
EPS Estimate Current Quarter | -0.2 |
EPS Estimate Next Quarter | -0.29 |
What analysts predicted
Upside of 51.43%
Sell
Neutral
Buy
Cymabay Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Cymabay Therapeutics Inc | 18.06% | 63.39% | 312.03% | 138.91% | 35.29% |
![]() Moderna, Inc. | -3.91% | -29.82% | -15.12% | 54.11% | 473.87% |
![]() Regeneron Pharmaceuticals, Inc. | -0.9% | 10.13% | 22.22% | 50.58% | 114.4% |
![]() Novo Nordisk A/s | 2.45% | 29.29% | 91.93% | 176.03% | 299.56% |
![]() Seagen, Inc. | 7.77% | 4.2% | 47.16% | 16.48% | 167.89% |
![]() Vertex Pharmaceuticals Incorporated | 2.14% | 18.37% | 27.77% | 35.7% | 98.94% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Cymabay Therapeutics Inc | NA | NA | 0.0 | -0.93 | -0.85 | -0.22 | 0.0 | 1.11 |
![]() Moderna, Inc. | 35.66 | 35.66 | 0.0 | -3.66 | 0.07 | 0.01 | 0.0 | 44.49 |
![]() Regeneron Pharmaceuticals, Inc. | 22.39 | 22.39 | 9.01 | 41.82 | 0.19 | 0.1 | 0.0 | 225.94 |
![]() Novo Nordisk A/s | 43.6 | 43.6 | 2.03 | 3.3 | 0.82 | 0.22 | 0.01 | 2.52 |
![]() Seagen, Inc. | NA | NA | 18.53 | -3.47 | -0.26 | -0.13 | 0.0 | 13.96 |
![]() Vertex Pharmaceuticals Incorporated | 27.75 | 27.75 | 0.41 | 14.71 | 0.25 | 0.16 | 0.0 | 60.01 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Cymabay Therapeutics Inc | Buy | $1.6B | 35.29% | NA | -260.27% |
![]() Moderna, Inc. | Buy | $39.6B | 473.87% | 35.66 | 11.33% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $90.8B | 114.4% | 22.39 | 33.93% |
![]() Novo Nordisk A/s | Buy | $834.9B | 299.56% | 43.6 | 33.4% |
![]() Seagen, Inc. | Hold | $38.9B | 167.89% | NA | -33.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $92.5B | 98.94% | 27.75 | 35.4% |
venBio Select Advisor LLC
HHG PLC
BlackRock Inc
Vanguard Group Inc
Octagon Capital Advisors LP
Adage Capital Partners Gp LLC
Cymabay Therapeutics Inc’s price-to-earnings ratio stands at None
Read Morecymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline.
Organization | Cymabay Therapeutics Inc |
Employees | 60 |
CEO | Mr. Sujal A. Shah |
Industry | Health Technology |
Wearable Devices Ltd
$14.64
-5.0%
Barrett Business Services Inc
$14.64
-5.0%
Simplify Interest Rate Hedge Etf
$14.64
-5.0%
Invesco S&p Smallcap 600® Pure Value Etf
$14.64
-5.0%
American Century Quality Diversified International Etf
$14.64
-5.0%
Short Dow30 Proshares
$14.64
-5.0%
Franklin Street Properties Corp
$14.64
-5.0%
Nuveen Credit Strat Incm
$14.64
-5.0%
Ishares Morningstar Value Etf
$14.64
-5.0%